{"preliminary_commentary":{"by_channel":{"x_thread":134,"youtube":14,"podcast":11,"bluesky_thread":8,"x_video":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05840016\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-10-29T02:12:03.165Z","note":"Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice.","passages_read":null,"text":"The commentary discusses HARMONi-6’s comparison of ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in advanced squamous NSCLC, and the rationale of combining PD-1 and VEGF targeting. Questions raised include whether the overall-survival pattern will persist at final analysis, how findings may translate beyond the study population, and how to interpret the older-patient signal. Discussion also covers bleeding-related eligibility exclusions, including hemoptysis, cavitation and vessel involvement, and their implications for patient selection."},"name":"HARMONi-6","nct_id":"NCT05840016","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=harmoni-6-nct05840016. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"AK112 will be administered at a selected dose intravenously (IV) every three weeks (Q3W). Carboplatin will be administered at AUC5, Q3W, intravenously (IV) for 4 cycles. Paclitaxel will be administered at 175 mg/m2, Q3W, intravenously (IV) for 4 cycles.","label":"Experimental: AK112 in Combination With Paclitaxel Plus Carboplatin","type":"EXPERIMENTAL"},{"description":"Tislelizumab will be administered at a dose of 200 mg intravenously (IV) every three weeks (Q3W). Carboplatin will be administered at AUC5, Q3W, intravenously (IV) for 4 cycles. Paclitaxel will be administered at 175 mg/m2, Q3W, intravenously (IV) for 4 cycles.","label":"Active Comparator: Tislelizumab in Combination With Paclitaxel Plus Carboplatin","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"conditions":["Advanced Squamous Non Small Cell Lung Cancer"],"enrollment":{"count":532,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"AK112, Carboplatin, Paxlitaxel","otherNames":[],"type":"DRUG"},{"name":"Tislelizumab, Carboplatin, Paxlitaxel","otherNames":[],"type":"DRUG"}],"last_update":"2025-05-02","lead_sponsor":"Akeso","official_title":"A Randomized, Controlled, Multi-center Phase III Clinical Study of AK112 Combined With Chemotherapy Versus PD-1 Inhibitor Combined With Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-02-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"PFS assessed by IRRC per RECIST v1.1","timeFrame":"Up to approximately 2 years"}],"references":[{"citation":"Chen Z, Yang F, Jiang Z, Sun L, Wu L, Han Z, Fan Y, Zhao Y, Li X, Xu H, Meng X, Liu Y, Zhang Z, Luo H, Ma X, Ma X, Shi Q, Zhang Z, Yang R, Wang P, Pan P, Ai X, Li J, Pu X, Wang Z, Fang J, He M, He Y, Guo S, Li J, Wang H, Zhang J, Chu Q, Liu X, Ying S, Wu H, Sun H, Ji Y, Zhou M, Cao C, Tang K, Li Z, Li D, Zhang Z, Li J, Zhou J, Yang H, Du Y, Yang H, Shi J, Chen H, Moore AC, Lu S. Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 study. Future Oncol. 2026 Jun;22(14):1637-1650. doi: 10.1080/14796694.2026.2676052. Epub 2026 Jun 3.","pmid":"42233228","type":"DERIVED"},{"citation":"Lu S, Liu B, Luo Y, Sun L, Wu L, Han Z, Fan Y, Zhao Y, Li X, Xu H, Meng X, Liu Y, Zhang Z, Luo H, Ma X, Ma X, Shi Q, Zhang Z, Yang R, Wang P, Pan P, Ai X, Li J, Pu X, Wang Z, Fang J, He M, He Y, Guo S, Li J, Wang H, Zhang J, Chu Q, Liu X, Ying S, Wu H, Sun H, Ji Y, Zhou M, Cao C, Tang K, Li Z, Li D, Zhang Z, Li J, Zhou J, Yang H, Du Y, Yang H, Shi J, Chen H, Chen Z, Li W, Lu D, Hu M, Wang ZM, Li B, Xia MY. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China. Lancet. 2026 Jun 27;407(10548):2620-2629. doi: 10.1016/S0140-6736(26)00966-9. Epub 2026 May 31.","pmid":"42218899","type":"DERIVED"}],"start_date":{"date":"2023-08-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT05840016"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/harmoni-6-nct05840016"}